Item 8.01 Other Events.
On December 19, 2022, Zymeworks Inc. (the "Company") issued a press release
announcing positive topline results from the Company's pivotal Phase 2b
HERIZON-BTC-01 open-label, single-arm clinical trial investigating zanidatamab,
a HER2-targeted bispecific antibody, as monotherapy in patients with previously
treated HER2-amplified and expressing biliary tract cancers. A copy of this
press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and
is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
99.1 Press Release, dated December 19, 2022.
104 Cover Page Interactive Data File (embedded as Inline XBRL document).
2
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses